Better Dark Horse Weight Loss Drug Stock: Pfizer Vs. Roche
Kamala Harris' Potential Impact on Health Care Stocks
With President Joe Biden earlier Sunday saying he will end his campaign for re-election and endorsing Vice President Kamala Harris, the focus now turns on her positions on issues.
Here Are Big Pharma's Leading Blockbuster Makers
Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.
Pfizer Options Spot-On: On July 19th, 130.08K Contracts Were Traded, With 3 Million Open Interest
On July 19th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 130.08K options for the day, of which put options accounted for 32.41% of the total transactions, and
Check Out What Whales Are Doing With PFE
Investors with a lot of money to spend have taken a bullish stance on Pfizer (NYSE:PFE).And retail traders should know.We noticed this today when the trades showed up on publicly available options
Dividend Roundup: Goldman Sachs, Johnson & Johnson, Qualcomm, Caterpillar, and More
What Are the Most Profitable Stocks of All Time? The Answer Might Surprise You.
An academic with a large following on Wall Street recently published a paper showing the stocks that have seen the strongest returns over time
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy.
Pfizer Options Spot-On: On July 18th, 266.35K Contracts Were Traded, With 2.96 Million Open Interest
On July 18th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 266.35K options for the day, of which put options accounted for 30.65% of the total transactions, and
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
More than half of the states in the U.S. are experiencing significant Covid-19 activity in wastewater, and President Joe Biden remains in isolation after announcing Wednesday he caught the virus for
Valneava and Pfizer Nearing Lyme Vaccine Milestone
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
On Wednesday, Pfizer Inc (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announced that the participants of the Phase 3 VALOR trial have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15.
Express News | President Biden's Doctor Says President Biden's Vital Signs Remain Normal; He Will Continue To Conduct U.S. Business; Continues To Receive Paxlovid; Still Experiencing Mild Covid-19 Symptoms
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Pfizer Inc (NYSE:PFE), one of the world's largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
New York, NY and Saint-Herblain (France), July 17, 2024 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the participants of the Phase 3 trial “Vaccine Against Lyme for Outdoor Recreationists” (VALOR) have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025.
Pfizer Options Spot-On: On July 17th, 236.13K Contracts Were Traded, With 2.92 Million Open Interest
On July 17th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 236.13K options for the day, of which put options accounted for 21.65% of the total transactions, and
Express News | OPKO Health Inc: Also Permits OPKO to Maintain Full Benefit of $100 Mln of Remaining Potential Milestone Payments From Pfizer
Express News | OPKO Health Enters Into $250M Non-Dilutive Note Purchase Agreement With HealthCare Royalty Secured By Profit Share Payments From Pfizer For NGENLA
Pfizer And Valneva Announce Primary Vaccination Series Completion In Phase 3 VALOR Lyme Disease Trial; Participants Completed Primary Vaccination Series (3 Doses) With VLA15
Participants completed primary vaccination series (3 doses) with VLA15Primary vaccination series to be followed by a booster approximately one year after completionNew York, NY and Saint-Herblain (